NEUROLEPTIC MALIGNANT SYNDROME

Abstract

Introduction: Malignant neuroleptic syndrome is a complication that occurs while taking high doses of drugs, more often antipsychotics. Its prevalence ranges from 0.02 to 3.23 %. This iatrogenic ышву уааусе develops within 4 weeks of starting therapy. Nevertheless, in 16 % of patients, symptoms are recorded after 24 hours. Objective: To analyze the results of studies reflecting the mechanisms of development, risk factors, prevalence, diagnostic criteria and principles of treatment of NMS. Materials and methods: We searched for full-text publications in Russian and English in the E-Library, PubMed databases using keywords. The sample consisted of 84 publications, including scientific articles and monographs on this scientific issue. The search depth was 10 years. In addition, earlier publications of historical interest were included in the lecture. Despite our comprehensive search of these commonly used databases and search terms, it cannot be excluded that some publications may have been missed. Results: The systematization of modern data on the etiology, risk factors and the theory of the pathophysiology of the NNS was carried out. It also describes the clinical picture, the criteria for making a diagnosis and possible treatment for a better understanding of practitioners who face this complication.